NKF's KidneyCAREâ„¢ Study Celebrates One-Year Milestone, Enrolling Over 1,000 Patients Nationwide
The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...
The Manila Times1h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one ...
Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report
By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the ...
Le Lézard11h
NKF's KidneyCAREtm Study Celebrates One-Year Milestone, Enrolling Over 1,000 Patients Nationwide
The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)tm Study ? the first national CKD patient registry that captures both ...